20 Jun 2024
The Impact Factor (IF) of ESMO journals has remained strong this year, according to the 2024 Journal Citation Reports published by Clarivate Analytics.
By disseminating high-quality science and fostering discussion on cutting-edge topics, Annals of Oncology has attained its highest impact factor to date for the 2023 citation year: 56.7, ranking 4/322 in the JCR oncology category. The latest IF for ESMO Open is 7.1.
Explore some of the cutting-edge articles that contributed to the latest IFs:
Annals of Oncology
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
- Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
ESMO Open
- Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN☆
- Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
- Artificial intelligence for detection of microsatellite instability in colorectal cancer—a multicentric analysis of a pre-screening tool for clinical application